Table 3. Comprehensive geriatric assessment; arm A: DG followed by erlotinib if progression, arm B: erlotinib followed by DG if progression.
| Arm A (n=48) | Arm B (n=51) | ||
|---|---|---|---|
| Score maximum | Mean score | (Min/max) | |
| Socioeconomic conditions | 12 | 11.5 (7/12) | 11.4 (8/12) |
| Cognitive assessment | 14 | 13.6 (10/14) | 13.5 (11/14) |
| Emotional status and depression scale | 9 | 0.8 (0/4) | 1 (0/6) |
| Sensorial status | 4 | 3.8 (3/4) | 3.8 (2/4) |
| Nutritional risk | 14 | 10.2 (5/14) | 10.2 (5/14) |
| QoL Iris scale | 6 | 5.4 (4/6) | 5.2 (3/6) |
| ADL | 6 | 6 (6/6) | 6 (6/6) |
| IADL | 4 | 4 (4/4) | 4 (4/4) |
| Incontinence scale | 4 | 4 (4/4) | 4 (4/4) |
| Falls and mobility | 10 | 9.8 (8/10) | 9.9 (9/10) |
| Pain | 32 | 7.9 (0/32) | 5.3 (0/24) |
| Global score (EGSK) | 20 | 18 (10/20) | 18 (10/20) |
| MMS de Folstein | 30 | 29.7 (25/30) | 29.7 (24/30) |
Abbreviations: ADL=activities of daily living; DG= docetaxel and gemcitabine; EGSK=name of software used for our CGA; IADL=instrumental of daily living; MMS=Mini Mental Status; QoL=quality of life.